Literature DB >> 22552030

Epicatechin ingested via cocoa products reduces blood pressure in humans: a nonlinear regression model with a Bayesian approach.

Sabine Ellinger1, Andreas Reusch, Peter Stehle, Hans-Peter Helfrich.   

Abstract

BACKGROUND: Four meta-analyses of randomized controlled trials (RCTs) based on the classical random-effects model showed that cocoa consumption can reduce systolic blood pressure (SBP) and diastolic blood pressure (DBP). Because epicatechin is suggested to be responsible for the treatment effect, changes in blood pressure should depend on the dose of ingested epicatechin, which may explain the between-study differences.
OBJECTIVE: The objective was to quantify the effect of epicatechin ingested via cocoa products on changes in SBP and DBP.
DESIGN: A nonlinear meta-regression model was chosen to investigate the impact of the epicatechin dose on changes in SBP and DBP. A Bayesian approach using Markov chain Monte Carlo methods was applied for an appropriate treatment of the nonlinearity.
RESULTS: Data from 16 RCTs on SBP and 15 RCTs on DBP were included. The dose of epicatechin ingested via cocoa products influenced the changes in SBP and DBP. The asymptotic limit for the reduction was estimated at -4.6 mm Hg (95% CI: -5.4, -3.9 mm Hg) for SBP and at -2.1 mm Hg (95% CI: -2.7, -1.6 mm Hg) for DBP. An intake of 25 mg epicatechin/d led to a mean reduction of -4.1 mm Hg (95% CI: -4.6, -3.6 mm Hg) in SBP and of -2.0 mm Hg (95% CI: -2.4, -1.5 mm Hg) in DBP.
CONCLUSIONS: Blood pressure reduction by consumption of cocoa products depends on the dose of ingested epicatechin, which explains most of the between-study differences in classical meta-analyses. Similar effects may be achieved by consumption of other foods that are also rich in epicatechin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552030     DOI: 10.3945/ajcn.111.029330

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  22 in total

1.  Tea and flavonoids: where we are, where to go next.

Authors:  Johanna T Dwyer; Julia Peterson
Journal:  Am J Clin Nutr       Date:  2013-10-30       Impact factor: 7.045

Review 2.  The role of nutrition and nutraceutical supplements in the treatment of hypertension.

Authors:  Mark Houston
Journal:  World J Cardiol       Date:  2014-02-26

3.  (-)-Epicatechin administration and exercising skeletal muscle vascular control and microvascular oxygenation in healthy rats.

Authors:  Steven W Copp; Tadakatsu Inagaki; Michael J White; Daniel M Hirai; Scott K Ferguson; Clark T Holdsworth; Gabrielle E Sims; David C Poole; Timothy I Musch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-09       Impact factor: 4.733

4.  (-)-Epicatechin is associated with increased angiogenic and mitochondrial signalling in the hindlimb of rats selectively bred for innate low running capacity.

Authors:  Maik Hüttemann; Icksoo Lee; Guy A Perkins; Steven L Britton; Lauren G Koch; Moh H Malek
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

5.  (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients.

Authors:  Israel Ramirez-Sanchez; Pam R Taub; Theodore P Ciaraldi; Leonardo Nogueira; Taylor Coe; Guy Perkins; Michael Hogan; Alan S Maisel; Robert R Henry; Guillermo Ceballos; Francisco Villarreal
Journal:  Int J Cardiol       Date:  2013-07-17       Impact factor: 4.164

6.  The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER).

Authors:  Aldo Moreno-Ulloa; David Mendez-Luna; Ernesto Beltran-Partida; Carmen Castillo; Gustavo Guevara; Israel Ramirez-Sanchez; José Correa-Basurto; Guillermo Ceballos; Francisco Villarreal
Journal:  Pharmacol Res       Date:  2015-08-21       Impact factor: 7.658

Review 7.  Nutrition and nutraceutical supplements for the treatment of hypertension: part III.

Authors:  Mark Houston
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-01       Impact factor: 3.738

8.  Flavonoid intake in European adults (18 to 64 years).

Authors:  Anna Vogiatzoglou; Angela A Mulligan; Marleen A H Lentjes; Robert N Luben; Jeremy P E Spencer; Hagen Schroeter; Kay-Tee Khaw; Gunter G C Kuhnle
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk).

Authors:  Anna Vogiatzoglou; Angela A Mulligan; Amit Bhaniani; Marleen A H Lentjes; Alison McTaggart; Robert N Luben; Christian Heiss; Malte Kelm; Marc W Merx; Jeremy P E Spencer; Hagen Schroeter; Kay-Tee Khaw; Gunter G C Kuhnle
Journal:  Free Radic Biol Med       Date:  2015-03-17       Impact factor: 7.376

10.  Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial.

Authors:  Verena Brüll; Constanze Burak; Birgit Stoffel-Wagner; Siegfried Wolffram; Georg Nickenig; Cornelius Müller; Peter Langguth; Birgit Alteheld; Rolf Fimmers; Stefanie Naaf; Benno F Zimmermann; Peter Stehle; Sarah Egert
Journal:  Br J Nutr       Date:  2015-09-02       Impact factor: 3.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.